期刊
ACS OMEGA
卷 7, 期 1, 页码 334-341出版社
AMER CHEMICAL SOC
DOI: 10.1021/acsomega.1c04711
关键词
-
资金
- JSPS KAKENHI [21H02873, 21K07659, 21H03635]
- AMED Moonshot Research and Development Program [21zf0127003h001]
- JSPS International Joint Research Program [JPJSBP120207203]
- Beijing Jishuitan Hospital Elite Young Scholar Programme [XKGG2021]
- Grants-in-Aid for Scientific Research [21K07659, 21H02873, 21H03635] Funding Source: KAKEN
The development of a novel PET tracer [Cu-64]CM-2 for mapping CD133 protein in various cancers demonstrates specific binding to CD133-positive CSCs in preclinical tumor models, making it a state-of-the-art tool for tracking CD133 dynamics and CSCs in refractory cancers.
CD133 has been recognized as a prominent biomarker for cancer stem cells (CSCs), which promote tumor relapse and metastasis. Here, we developed a clinically relevant, stable, and peptide-based positron emission tomography (PET) tracer, [Cu-64]CM-2, for mapping CD133 protein in several kinds of cancers. Through the incorporation of a 6-aminohexanoic acid (Ahx) into the N terminus of a CM peptide, we constructed a stable peptide tracer [Cu-64]CM-2, which exhibited specific binding to CD133-positive CSCs in multiple preclinical tumor models. Both PET imaging and ex vivo biodistribution verified the superb performance of [Cu-64]CM-2. Furthermore, the matched physical and biological half-life of [Cu-64]CM-2 makes it a state-of-the-art PET tracer for CD133. Therefore, [Cu-64]CM-2 PET may not only enable the longitudinal tracking of CD133 dynamics in the cancer stem cell niche but also provide a powerful and noninvasive imaging tool to track down CSCs in refractory cancers.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据